The Runx transcriptional co-activator, CBFβ, is essential for invasion of breast cancer cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Mendoza Villanueva, Daniel ^a   Deng, Wensheng ^a   Lopez Camacho, Cesar ^a   Shore, Paul ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GALECTIN 3; GELATINASE B; OSTEOCALCIN; OSTEOPONTIN; TRANSCRIPTION FACTOR CBF BETA; TRANSCRIPTION FACTOR RUNX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; CORE BINDING FACTOR BETA;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER INVASION; CELL INVASION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; ANIMAL; BREAST TUMOR; FEMALE; GENETICS; METASTASIS; MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CORE BINDING FACTOR BETA SUBUNIT; FEMALE; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA INTERFERENCE;

EID: 77954051530     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-171     Document Type: Article

References (33)

1. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res 2008, 99:33-76. full_text, 18037406.
2. Zhang L, Lukasik SM, Speck NA, Bushweller JH. Structural and functional characterization of Runx1, CBF beta, and CBF beta-SMMHC. Blood Cells Mol Dis 2003, 30:147-156. 10.1016/S1079-9796(03)00022-6, 12732176.
3. Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, Kumasaka T, Yamamoto M, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell 2001, 104:755-767. 10.1016/S0092-8674(01)00271-9, 11257229.
4. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764. 10.1016/S0092-8674(00)80258-5, 9182763.
5. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996, 84:321-330. 10.1016/S0092-8674(00)80986-1, 8565077.
6. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 1996, 93:3444-3449. 10.1073/pnas.93.8.3444, 39628, 8622955.
7. Robertson AJ, Dickey-Sims C, Ransick A, Rupp DE, McCarthy JJ, Coffman JA. CBFbeta is a facultative Runx partner in the sea urchin embryo. BMC Biol 2006, 4:4. 10.1186/1741-7007-4-4, 1395345, 16469111.
8. Coffman JA. Is Runx a linchpin for developmental signaling in metazoans?. J Cell Biochem 2009, 107:194-202. 10.1002/jcb.22143, 2762205, 19330799.
9. Yokomizo T, Yanagida M, Huang G, Osato M, Honda C, Ema M, Takahashi S, Yamamoto M, Ito Y. Genetic evidence of PEBP2beta-independent activation of Runx1 in the murine embryo. Int J Hematol 2008, 88:134-138. 10.1007/s12185-008-0121-4, 18594778.
10. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 2005, 102:1454-1459. 10.1073/pnas.0409121102, 547873, 15665096.
11. Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ, Bellahcene A, Van Wijnen AJ, Young MF, Lian JB, et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003, 63:2631-2637.
12. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005, 25:8581-8591. 10.1128/MCB.25.19.8581-8591.2005, 1265732, 16166639.
13. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006, 25:589-600. 10.1007/s10555-006-9032-0, 17165130.
14. Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem 2005, 96:484-489. 10.1002/jcb.20557, 16052475.
15. Selvamurugan N, Kwok S, Partridge NC. Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. J Biol Chem 2004, 279:27764-27773. 10.1074/jbc.M312870200, 15084595.
16. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J 2004, 19:543-549. 10.1023/B:GLYC.0000014084.01324.15, 14758078.
17. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008, 27:103-118. 10.1007/s10555-007-9104-9, 18049863.
18. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246. 10.1038/sj.onc.1202799, 10435636.
19. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 2007, 102:859-868. 10.1002/jcb.21520, 17721886.
20. Inman CK, Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 2003, 278:48684-48689. 10.1074/jbc.M308001200, 14506237.
21. Stock M, Schafer H, Stricker S, Gross G, Mundlos S, Otto F. Expression of galectin-3 in skeletal tissues is controlled by Runx2. J Biol Chem 2003, 278:17360-17367. 10.1074/jbc.M207631200, 12604608.
22. Yoshida CA, Furuichi T, Fujita T, Fukuyama R, Kanatani N, Kobayashi S, Satake M, Takada K, Komori T. Core-binding factor beta interacts with Runx2 and is required for skeletal development. Nat Genet 2002, 32:633-638. 10.1038/ng1015, 12434152.
23. Gu TL, Goetz TL, Graves BJ, Speck NA. Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1). Mol Cell Biol 2000, 20:91-103. 10.1128/MCB.20.1.91-103.2000, 85059, 10594012.
24. Kim WY, Sieweke M, Ogawa E, Wee HJ, Englmeier U, Graf T, Ito Y. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. Embo J 1999, 18:1609-1620. 10.1093/emboj/18.6.1609, 1171248, 10075931.
25. Bollerot K, Romero S, Dunon D, Jaffredo T. Core binding factor in the early avian embryo: cloning of Cbfbeta and combinatorial expression patterns with Runx1. Gene Expr Patterns 2005, 6:29-39. 10.1016/j.modgep.2005.05.003, 16033710.
26. Lee J, Ahnn J, Bae SC. Homologs of RUNX and CBF beta/PEBP2 beta in C. elegans. Oncogene 2004, 23:4346-4352. 10.1038/sj.onc.1207669, 15156192.
27. Gorczynski MJ, Grembecka J, Zhou Y, Kong Y, Roudaia L, Douvas MG, Newman M, Bielnicka I, Baber G, Corpora T, et al. Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem Biol 2007, 14:1186-1197. 10.1016/j.chembiol.2007.09.006, 17961830.
28. DeMorrow S, Francis H, Gaudio E, Ueno Y, Venter J, Onori P, Franchitto A, Vaculin B, Vaculin S, Alpini G. Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. Am J Physiol Gastrointest Liver Physiol 2008, 294:G506-519. 10.1152/ajpgi.00304.2007, 18096608.
29. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, Wozney JM, Kim EG, Choi JY, Ryoo HM, Bae SC. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000, 20:8783-8792. 10.1128/MCB.20.23.8783-8792.2000, 86511, 11073979.
30. Inman CK, Li N, Shore P. Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. Mol Cell Biol 2005, 25:3182-3193. 10.1128/MCB.25.8.3182-3193.2005, 1069618, 15798204.
31. Mengshol JA, Vincenti MP, Brinckerhoff CE. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 2001, 29:4361-4372. 10.1093/nar/29.21.4361, 60184, 11691923.
32. Spencer VA, Sun JM, Li L, Davie JR. Chromatin immunoprecipitation: a tool for studying histone acetylation and transcription factor binding. Methods 2003, 31:67-75. 10.1016/S1046-2023(03)00089-6, 12893175.
33. Zhang HY, Jin L, Stilling GA, Ruebel KH, Coonse K, Tanizaki Y, Raz A, Lloyd RV. RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocrine 2009, 35:101-111. 10.1007/s12020-008-9129-z, 19020999.